Literature DB >> 19219404

Dapsone induced methemoglobinemia in a patient with glioblastoma.

Julie G Walker1, Tapan Kadia, Latrondria Brown, Harinder S Juneja, John F de Groot.   

Abstract

Primary brain tumor patients have multiple risk factors for Pneumocystis jiroveci and may require prophylaxis with TMP-SMZ or dapsone. Although dapsone is generally safe and efficacious, we present a case of a patient diagnosed with a brain stem glioblastoma who developed methemoglobinemia and haemolytic anemia after presenting with worsening confusion and cardiopulmonary system dysfunction. This case highlights one of the potentially severe complications associated with dapsone therapy. Although this illustrates an unusual toxicity of dapsone, a high index of suspicion should be given to high-risk patients due to ethnic heritage, anemia, or advanced age. Furthermore, given the toxicities of TMP-SMZ and dapsone, further work is needed to determine the threshold CD4(+) count at which empiric prophylaxis should be initiated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19219404      PMCID: PMC4438990          DOI: 10.1007/s11060-009-9813-8

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  19 in total

1.  The sulfone syndrome secondary to dapsone prophylaxis in a patient undergoing unrelated hematopoietic stem cell transplantation.

Authors:  Muneer H Abidi; Jennifer R Kozlowski; Rami B Ibrahim; Edward Peres
Journal:  Hematol Oncol       Date:  2006-09       Impact factor: 5.271

2.  Size-dependent oxygenation and energy status in multicellular tumor spheroids.

Authors:  S Walenta; J Dötsch; B Bourrat-Flöck; W Mueller-Klieser
Journal:  Adv Exp Med Biol       Date:  1990       Impact factor: 2.622

Review 3.  Glucose-6-phosphate dehydrogenase deficiency.

Authors:  E Beutler
Journal:  N Engl J Med       Date:  1991-01-17       Impact factor: 91.245

Review 4.  The molecular basis of glucose-6-phosphate dehydrogenase deficiency.

Authors:  T Vulliamy; P Mason; L Luzzatto
Journal:  Trends Genet       Date:  1992-04       Impact factor: 11.639

Review 5.  Methemoglobin--it's not just blue: a concise review.

Authors:  Jay Umbreit
Journal:  Am J Hematol       Date:  2007-02       Impact factor: 10.047

6.  Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection.

Authors:  Michael A Hughes; Michele Parisi; Stuart Grossman; Lawrence Kleinberg
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-08-01       Impact factor: 7.038

7.  The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients.

Authors:  M D Coleman; L E Rhodes; A K Scott; J L Verbov; P S Friedmann; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

8.  Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for pneumocystis carinii pneumonia (PCP) prophylaxis: a correlation with cytochrome b5 reductase (Cb5R) enzyme levels.

Authors:  Suzan Williams; Paula MacDonald; James D Hoyer; Ronald Duncan Barr; Uma Harish Athale
Journal:  Pediatr Blood Cancer       Date:  2005-01       Impact factor: 3.167

9.  Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.

Authors:  Y B Su; Sejean Sohn; Susan E Krown; Philip O Livingston; Jedd D Wolchok; Carolyn Quinn; Linda Williams; Theresa Foster; Kent A Sepkowitz; Paul B Chapman
Journal:  J Clin Oncol       Date:  2004-01-15       Impact factor: 44.544

10.  Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals.

Authors:  Rachel Ash-Bernal; Robert Wise; Scott M Wright
Journal:  Medicine (Baltimore)       Date:  2004-09       Impact factor: 1.889

View more
  5 in total

Review 1.  Dapsone in dermatology and beyond.

Authors:  Gottfried Wozel; Christian Blasum
Journal:  Arch Dermatol Res       Date:  2013-12-06       Impact factor: 3.017

2.  Dapsone-associated methemoglobinemia in a patient with slow NAT2*5B haplotype and impaired cytochrome b5 reductase activity.

Authors:  Mahmoud Abouraya; James C Sacco; Kristie Hayes; Sajeve Thomas; Craig S Kitchens; Lauren A Trepanier
Journal:  J Clin Pharmacol       Date:  2012-02       Impact factor: 3.126

Review 3.  Recommendations for diagnosis and treatment of methemoglobinemia.

Authors:  Achille Iolascon; Paola Bianchi; Immacolata Andolfo; Roberta Russo; Wilma Barcellini; Elisa Fermo; Gergely Toldi; Stefano Ghirardello; Davis Rees; Richard Van Wijk; Antonis Kattamis; Patrick G Gallagher; Noemi Roy; Ali Taher; Razan Mohty; Andreas Kulozik; Lucia De Franceschi; Antonella Gambale; Mariane De Montalembert; Gian Luca Forni; Cornelis L Harteveld; Josef Prchal
Journal:  Am J Hematol       Date:  2021-09-23       Impact factor: 13.265

4.  Pneumocystis jirovecii prophylaxis in patients treated for high-grade gliomas: a survey among neuro-oncologists.

Authors:  Nebojša Skorupan; Surabhi Ranjan; Seema Mehta; Olga Yankulina; Nathan Nenortas; Stuart Grossman; Xiaobu Ye; Matthias Holdhoff
Journal:  Neurooncol Pract       Date:  2018-11-29

5.  In Vitro Protective Effect and Antioxidant Mechanism of Resveratrol Induced by Dapsone Hydroxylamine in Human Cells.

Authors:  Rosyana V Albuquerque; Nívea S Malcher; Lílian L Amado; Michael D Coleman; Danielle C Dos Santos; Rosivaldo Sa Borges; Sebastião Aldo S Valente; Vera C Valente; Marta Chagas Monteiro
Journal:  PLoS One       Date:  2015-08-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.